tiprankstipranks
Advertisement
Advertisement
Alterity Therapeutics provides corporate update
PremiumThe FlyAlterity Therapeutics provides corporate update
3M ago
Alterity Therapeutics highlights key 2026 objectives
Premium
The Fly
Alterity Therapeutics highlights key 2026 objectives
3M ago
Alterity Therapeutics initiated with a Speculative Buy at Canaccord
Premium
The Fly
Alterity Therapeutics initiated with a Speculative Buy at Canaccord
4M ago
Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler
PremiumThe FlyMeet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler
5M ago
Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
Premium
The Fly
Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
5M ago
Alterity Therapeutics reports cash balance of A$54.46M as of September 30
Premium
The Fly
Alterity Therapeutics reports cash balance of A$54.46M as of September 30
6M ago
Alterity Therapeutics Sets AGM and Director Nomination Dates
PremiumCompany AnnouncementsAlterity Therapeutics Sets AGM and Director Nomination Dates
7M ago
Alterity Therapeutics presents ATH434-201 Phase 2 data
Premium
The Fly
Alterity Therapeutics presents ATH434-201 Phase 2 data
7M ago
Alterity Therapeutics raises A$20M in strategic placement
Premium
The Fly
Alterity Therapeutics raises A$20M in strategic placement
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100